Trevi Therapeutics (NASDAQ:TRVI) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a sell rating in a research note published on Saturday.

Several other brokerages have also issued reports on TRVI. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Friday, April 17th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday, July 17th. Morgan Stanley reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Finally, B. Riley Financial lifted their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Trevi Therapeutics presently has an average rating of “Buy” and an average price target of $24.91.

Trevi Therapeutics Stock Up 3.4%

NASDAQ:TRVI opened at $18.12 on Friday. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -56.62 and a beta of 1.00. Trevi Therapeutics has a 52 week low of $6.55 and a 52 week high of $20.22. The firm has a 50 day moving average of $16.20 and a 200 day moving average of $13.56.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, analysts expect that Trevi Therapeutics will post -0.47 EPS for the current year.

Institutional Trading of Trevi Therapeutics

Large investors have recently added to or reduced their stakes in the company. KBC Group NV acquired a new position in shares of Trevi Therapeutics in the first quarter valued at about $29,000. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $50,000. Russell Investments Group Ltd. boosted its position in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after buying an additional 2,996 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after buying an additional 1,523 shares during the period. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.